Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Exclusion Criteria

• •History of Grade 3 or higher cytokine release syndrome (CRS) associated with any T-cell redirecting therapy (e.g., CD3-redirecting technologies or CAR-T cell therapy);
• •Prior anti-myeloma therapies within the specified timeframes before enrollment:
• •* Previous treatment with GPRC5D-targeted therapy;
• •* Genetically modified adoptive cell therapy (e.g., chimeric antigen receptor T-cell \[CAR-T\], natural killer \[NK\] cell therapy) within 3 months;
• •* Targeted therapy, investigational drugs, or invasive investigational medical devices within 21 days or 5 half-lives (whichever is longer);
• •* Monoclonal antibodies or bispecific antibody therapy for multiple myeloma within 21 days or 5 half-lives (whichever is longer);
• •* Cytotoxic therapy within 21 days;
• •* Proteasome inhibitor therapy within 14 days;
• •* Immunomodulatory drug therapy within 7 days;
• •Radiotherapy within 14 days (except low-dose palliative radiation \[10-30 Gy\]);
• •Prior intolerance to Pomalidomide (applies to treatment cohorts containing Pomalidomide);
• •Prior intolerance to Bortezomib (applies to treatment cohorts containing bortezomid);
• •Prior intolerance to Lenalidomide (applies to treatment cohorts containing Lenalidomide);
• •Prior intolerance to Daratumumab (applies to treatment cohorts containing Daratumumab).